Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
作者信息
Tanne Janice Hopkins
机构信息
New York.
出版信息
BMJ. 2023 Mar 16;380:628. doi: 10.1136/bmj.p628.
DOI:10.1136/bmj.p628
PMID:36927755
Abstract
摘要
相似文献
1
Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.乐卡奈单抗：美国退伍军人健康管理局将承担新型阿尔茨海默病药物的费用。
BMJ. 2023 Mar 16;380:628. doi: 10.1136/bmj.p628.
2
Lecanemab (Leqembi) for Alzheimer's disease.用于治疗阿尔茨海默病的来卡奈单抗（Leqembi）。
Med Lett Drugs Ther. 2023 Feb 6;65(1669):17-18. doi: 10.58347/tml.2023.1669a.
3
Lecanemab: First Approval.莱卡奈单抗：首次获批。
Drugs. 2023 Mar;83(4):359-365. doi: 10.1007/s40265-023-01851-2.
4
FDA approves Alzheimer's drug lecanemab amid safety concerns.尽管存在安全担忧，美国食品药品监督管理局仍批准了治疗阿尔茨海默病的药物lecanemab。
Nature. 2023 Jan;613(7943):227-228. doi: 10.1038/d41586-023-00030-3.
5
Lecanemab (Leqembi) granted full approval for early Alzheimer's disease.仑卡奈单抗（Leqembi）获早期阿尔茨海默病全面批准。
Med Lett Drugs Ther. 2023 Aug 21;65(1683):129-130. doi: 10.58347/tml.2023.1683a.
6
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.早期阿尔茨海默病患者淀粉样蛋白正电子发射断层扫描和血浆生物标志物的群体药代动力学-药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27.
7
Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.阿尔茨海默病：尽管存在成本和安全方面的担忧，美国食品药品监督管理局仍批准了仑卡奈单抗。
BMJ. 2023 Jan 11;380:73. doi: 10.1136/bmj.p73.
8
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.利斯卡尼单抗治疗早期阿尔茨海默病患者：来自 2 期概念验证研究随机和开放标签扩展的生物标志物、认知和临床效果的详细结果。
Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.
9
Unblinding in the lecanemab trial in Alzheimer's disease.在阿尔茨海默病的lecanemab试验中揭盲。
Brain. 2023 Nov 2;146(11):e100. doi: 10.1093/brain/awad171.
10
Evidence for lecanemab in early Alzheimer's disease.仑卡奈单抗治疗早期阿尔茨海默病的证据。
Drug Ther Bull. 2023 Mar;61(3):37. doi: 10.1136/dtb.2023.000005. Epub 2023 Feb 1.
引用本文的文献
1
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.仑卡奈单抗：用于早期阿尔茨海默病治疗的同类第二种疗法。
Innov Pharm. 2024 Mar 18;15(1). doi: 10.24926/iip.v15i1.5787. eCollection 2024.
2
Association between military service and Alzheimer's disease neuropathology at autopsy.军人服务与尸检阿尔茨海默病神经病理学之间的关联。
Alzheimers Dement. 2024 Feb;20(2):1468-1474. doi: 10.1002/alz.13520. Epub 2023 Nov 15.
3
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).早发性 AD 的淀粉样蛋白和 tau-PET：来自纵向早发性阿尔茨海默病研究（LEADS）的基线数据。
Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S98-S114. doi: 10.1002/alz.13453. Epub 2023 Sep 10.
Zotero 插件